Advancing Clinical Use of Neurofilament Light Chain: Translational Insights From Research to Routine Practice
Biomarker Insights · 2025-11 · 20
DOI: 10.1177/11772719251364018 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biomarker Insights, online erschienen am 27.10.2025. Verfasst von Evelina La Civita und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational Medical Sciences, Federico II University of Naples, Italy. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Neurofilament Light Chain (NfL) has emerged as a promising biomarker for neurological diseases. NfL, a structural component of axons, is released into cerebrospinal fluid (CSF) and blood following neuro-axonal damage. Highly sensitive immunometric assays have enabled its reliable quantification in blood, facilitating non-invasive monitoring. Several studies demonstrated strong correlations between NfL levels and the risk of developing different neurological diseases and, in individuals already living with a neurological disease, with the risk of worsening. However, interpretation is affected by factors like age, BMI, renal function, and comorbidities. NfL is already utilized as a diagnostic and prognostic biomarker in clinical practice, particularly in specialized centers and research settings, although no FDA-cleared assay is currently available for routine use. Recent research has highlighted that NfL may represent the first of a new generation of neurological biomarkers, with many more ready to come, such as glial fibrillary acidic protein (GFAP), further improving diagnostic and prognostic accuracy. Despite its promising role in the landscape of biomarkers, challenges remain to implement NfL in daily clinical practice, including standardization of assays, defining reference values, and ensuring methodological consistency. Addressing these limitations will be essential for integrating NfL into routine clinical practice, ultimately advancing precision medicine in neurology.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Translational Medical Sciences, Federico II University of Naples, Italy.
- Department of Neuroscience, Reproductive Science and Odontostomatology, Federico II University of Naples, Italy.
- Division of Laboratory Medicine - Civil Hospital "Maria SS. Addolorata"- Eboli, Salerno, Italy.
- Department of Molecular Medicine and Medical Biotechnology, Federico II University of Naples, Italy.
- Centre for Advanced Biotechnology (CEINGE), Naples, Italy.
- Multiple Sclerosis Unit, Policlinico Federico II University Hospital, Naples, Italy.
Zitieren
APA
La Civita, E., Nicolella, V., Fiorenza, M., Cosimato, V., Castaldo, G., Morra, V. B., Moccia, M., & Terracciano, D. (2025). Advancing Clinical Use of Neurofilament Light Chain: Translational Insights From Research to Routine Practice. Biomarker Insights, 20. https://doi.org/10.1177/11772719251364018
Vancouver
La Civita E, Nicolella V, Fiorenza M, Cosimato V, Castaldo G, Morra VB, et al. Advancing Clinical Use of Neurofilament Light Chain: Translational Insights From Research to Routine Practice. Biomarker Insights. 2025;20. doi:10.1177/11772719251364018
BibTeX
@article{LaCivita2025,
author = {La Civita, Evelina and Nicolella, Valerio and Fiorenza, Mariano and Cosimato, Vincenzo and Castaldo, Giuseppe and Morra, Vincenzo Brescia and Moccia, Marcello and Terracciano, Daniela},
title = {Advancing Clinical Use of Neurofilament Light Chain: Translational Insights From Research to Routine Practice},
journal = {Biomarker Insights},
year = {2025},
volume = {20},
doi = {10.1177/11772719251364018}
}
EUVIMED